Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS)

Aileen Cleary Cohen, MD, PhD, Ying-Wen Huang, MS, Alessandra Cesano, M.D., Ph.D., Rachael E. Hawtin, Ph.D., Jodi R. Ware, PharmD, Bishmaraj Arulrajah, B.S., Steven M. Kornblau, MD

Blood (2011) 118 (21): 2788.

https://doi.org/10.1182/blood.V118.21.2788.2788

Published: 2011

Journal Articles

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Norman J. Lacayo, MD, Todd A. Alonzo, PhD, Urte Gayko, Ph.D., Matt Westfall, Ph.D., Norman Purvis, Ph.D., Santosh Putta, Ph.D., James Hackett, Ph.D., Aileen Cleary Cohen, MD, PhD, Robert B. Gerbing, M.A., Gary V Dahl, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3544.

https://doi.org/10.1182/blood.V118.21.3544.3544

Published: 2011

Journal Articles

Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML.

Aileen Cleary Cohen, MD, PhD, Nancy Davidson, JD, Jason Scharf, MBA, Derek Middlebrook, MBA

Blood (2009) 114 (22): 4531.

https://doi.org/10.1182/blood.V114.22.4531.4531

Published: 2009

Journal Articles

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

M. D. Minden, MD, PhD, Steven M. Kornblau, MD, David B. Rosen, PhD, Aileen Cleary Cohen, MD, PhD, Urte Gayko, PhD, Santosh Putta, PhD, John Woronicz, PhD, Wendy J. Fantl, PhD, Alessandra Cesano, MD, PhD

Blood (2009) 114 (22): 1588.

https://doi.org/10.1182/blood.V114.22.1588.1588

Published: 2009

Journal Articles

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

Alessandra Cesano, MD, PhD, John Woronicz, PhD, Aileen Cleary Cohen, MD, PhD, Todd Covey, Santosh Putta, PhD, Urte Gayko, PhD, Wendy J. Fantl, PhD, S.M. Kornblau, M.D.

Blood (2009) 114 (22): 397.

https://doi.org/10.1182/blood.V114.22.397.397

Published: 2009

Journal Articles

High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).

Wendy J. Fantl, PhD, Rolla L. Yafawi, BS, Santosh K. Putta, PhD, Ying-Wen Huang, MS, Helen L. Francis-Lang, PhD, Rassenti Z. Laura, PhD, Aileen Cleary Cohen, MD, PhD, Thomas J. Kipps, MD, PhD

Blood (2007) 110 (11): 743.

https://doi.org/10.1182/blood.V110.11.743.743

Published: 2007

NARROW

Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS)

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML.

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).

Email alerts

ASH Publications

American Society of Hematology

Single Cell Network Profiling (SCNP) Reveals Age-and Disease-Based Heterogeneity in Healthy Individuals and in Patients with Low Risk (LR) Myelodysplastic Syndrome (MDS)

Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results,

Cost Burden Analysis of Ineffective Induction Chemotherapy in Elderly Patients with AML.

FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.

Single Cell Network Profiling as a Tool to Identify AML Chemotherapy Resistant Cell Phenotypes Under In Vivo Therapeutic Pressure.

High Level Phosphatase Activity Revealed in Chronic Lymphocytic Leukemia Cells That Use Mutated Immunoglobulin Heavy Chain Variable Region Genes and Lack High-Level Expression of the Zeta-Associated Protein 70 (ZAP-70).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only